Corvus Pharmaceuticals (CRVS) Competitors $5.17 -0.03 (-0.58%) As of 10:51 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRVS vs. EVO, IMCR, TVTX, PRAX, KNSA, OCUL, ARVN, RCUS, NRIX, and NTLAShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Evotec (EVO), Immunocore (IMCR), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), Arvinas (ARVN), Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Evotec Immunocore Travere Therapeutics Praxis Precision Medicines Kiniksa Pharmaceuticals Ocular Therapeutix Arvinas Arcus Biosciences Nurix Therapeutics Intellia Therapeutics Evotec (NASDAQ:EVO) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Which has preferable valuation and earnings, EVO or CRVS? Corvus Pharmaceuticals has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$777.05M1.84-$90.82MN/AN/ACorvus PharmaceuticalsN/AN/A-$27.03M-$0.93-5.56 Does the media prefer EVO or CRVS? In the previous week, Corvus Pharmaceuticals had 8 more articles in the media than Evotec. MarketBeat recorded 11 mentions for Corvus Pharmaceuticals and 3 mentions for Evotec. Evotec's average media sentiment score of 0.91 beat Corvus Pharmaceuticals' score of 0.59 indicating that Evotec is being referred to more favorably in the media. Company Overall Sentiment Evotec Positive Corvus Pharmaceuticals Positive Does the MarketBeat Community believe in EVO or CRVS? Corvus Pharmaceuticals received 285 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes654.55% Underperform Votes545.45% Corvus PharmaceuticalsOutperform Votes29161.91% Underperform Votes17938.09% Do insiders and institutionals have more ownership in EVO or CRVS? 5.8% of Evotec shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is EVO or CRVS more profitable? Evotec's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Corvus Pharmaceuticals N/A -70.71%-45.90% Do analysts recommend EVO or CRVS? Evotec presently has a consensus price target of $5.93, indicating a potential upside of 46.86%. Corvus Pharmaceuticals has a consensus price target of $12.38, indicating a potential upside of 139.36%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk and volatility, EVO or CRVS? Evotec has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. SummaryCorvus Pharmaceuticals beats Evotec on 10 of the 15 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$332.21M$6.54B$5.25B$8.82BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-5.5610.3986.5916.99Price / SalesN/A187.511,086.05116.59Price / CashN/A57.6843.2137.77Price / Book6.544.945.094.93Net Income-$27.03M$154.11M$122.23M$228.39M7 Day Performance-10.09%-6.93%-3.85%-3.27%1 Month Performance-29.95%-1.76%0.09%0.54%1 Year Performance120.94%-3.55%25.50%14.08% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.606 of 5 stars$5.17-0.6%$12.38+139.4%+122.2%$332.21MN/A-5.5630Analyst ForecastShort Interest ↑EVOEvotec1.9255 of 5 stars$4.44-0.4%$5.93+33.6%-54.0%$1.57B$777.05M0.005,061Short Interest ↑Gap DownIMCRImmunocore2.2611 of 5 stars$29.97+0.4%$65.64+119.0%-58.0%$1.50B$296.31M-31.55497News CoverageTVTXTravere Therapeutics2.7236 of 5 stars$18.92+0.3%$23.67+25.1%+95.1%$1.48B$203.45M-4.16460PRAXPraxis Precision Medicines1.9282 of 5 stars$78.11-3.5%$146.33+87.3%+47.6%$1.46B$1.61M-7.58110Short Interest ↑Gap DownKNSAKiniksa Pharmaceuticals2.6649 of 5 stars$20.10-1.0%$36.60+82.1%-3.7%$1.45B$384.10M-143.56220Analyst ForecastNews CoverageOCULOcular Therapeutix3.1353 of 5 stars$8.95+2.2%$16.71+86.8%+85.2%$1.41B$61.44M-6.78267Positive NewsARVNArvinas2.6424 of 5 stars$20.17-1.6%$63.50+214.8%-53.5%$1.39B$161.10M-4.32445RCUSArcus Biosciences1.8248 of 5 stars$14.97-0.6%$34.00+127.1%-20.2%$1.37B$263M-4.75500NRIXNurix Therapeutics2.2429 of 5 stars$19.31-2.0%$30.35+57.2%+102.9%$1.37B$56.42M-6.64300News CoverageNTLAIntellia Therapeutics4.5293 of 5 stars$12.70+4.7%$54.94+332.6%-63.7%$1.29B$43.09M-2.33600Analyst ForecastNews Coverage Related Companies and Tools Related Companies Evotec Alternatives Immunocore Alternatives Travere Therapeutics Alternatives Praxis Precision Medicines Alternatives Kiniksa Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Arvinas Alternatives Arcus Biosciences Alternatives Nurix Therapeutics Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRVS) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersGreatest crypto bull market in history?A crypto storm is coming Right now, conditions are in place for a historic move we expect will be the great...Stansberry Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored$24 trillion tech spotted at Mar-a-Lago?President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…Centurion Publishing | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
